Final Report Says Novartis May Have Falsified Data In Japan Diovan Trial
This article was originally published in PharmAsia News
Executive Summary
Novartis provide inconsistent data during a Japan study of its Diovan (valsartan) hypertension drug and may have deliberately falsified some of the data, according to a third-party investigation for Chiba University.